Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Ear, Nose, Mouth and ThroatDRG 151-epistaxis-without-mcc
    Ask Trek AI about this page

    Epistaxis without MCC: Inpatient Reimbursement Overview

    DRG 151 addresses inpatient admissions for epistaxis without Major Complication or Comorbidity, focusing on cases where nasal bleeding is the principal diagnosis. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because it determines grouping and payment under the Medicare prospective payment framework.

    Customize your policy alerts

    Sign up for drg 151 policy alerts

    Get alerted when payer policies referencing 151 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 151 Overview

    DRG 151 covers inpatient admissions for epistaxis without Major Complication or Comorbidity. This Diagnosis-Related Group applies to cases where nasal bleeding is the principal diagnosis and no major complications or comorbid conditions are coded. It matters for Medicare payment because it groups clinically similar hospital stays to determine a standardized prospective payment amount for inpatient services. Accurate coding of associated conditions influences hospital reimbursement under the Medicare inpatient prospective payment system.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute hemostatic intervention trials: randomized or pragmatic studies comparing different immediate in-hospital strategies for controlling active anterior or posterior epistaxis (for example, types of nasal packing materials, topical hemostatic agents, or endoscopic versus bedside cautery approaches). These trials enroll adults presenting to emergency departments or admitted for epistaxis without major comorbid complications and assess time to bleeding control, need for escalation to operative intervention, transfusion rates, and length of stay. Results inform clinicians about the most effective, rapid control methods and help payers understand resource use differences tied to procedural versus conservative management.
    • Comparative effectiveness and anticoagulation-management studies: observational cohorts or prospective comparative studies evaluating outcomes of patients on different antithrombotic regimens (antiplatelet agents, warfarin, direct oral anticoagulants) who develop epistaxis, including protocols for reversal, temporary holding, or continuation. These studies focus on typical inpatient populations older adults with cardiovascular comorbidities, measuring rebleeding, thrombotic events, readmissions, and costs associated with hospital stay and additional interventions. Findings are highly relevant for providers balancing bleeding and thrombotic risk and for payers seeking evidence-based pathways that minimize readmissions and downstream costs.
    • Post-discharge outcomes and quality-of-life studies: prospective observational studies or registry-based analyses tracking patients treated for epistaxis without major complications after hospital discharge to evaluate recurrence rates, need for outpatient ENT procedures, patient-reported nasal symptoms, and health-care utilization over 30–90 days. These studies enroll the broad DRG population discharged after resolution of bleeding and examine predictors of recurrence (e.g., anticoagulation status, prior nasal surgery, hypertension control) and the effectiveness of outpatient follow-up pathways. Results guide development of discharge planning, follow-up timing, and prevention strategies that can reduce readmissions and overall payer costs while improving patient-centered outcomes.

    Related Codes

    135-SINUS-AND-MASTOID-PROCEDURES-WITH-CC-MCC

    Sinus and Mastoid Procedures with CC/MCC: Inpatient Reimbursement Overview

    136-SINUS-AND-MASTOID-PROCEDURES-WITHOUT-CC-MCC

    Sinus and Mastoid Procedures without CC/MCC: Inpatient Reimbursement Overview

    137-MOUTH-PROCEDURES-WITH-CC-MCC

    Mouth Procedures with CC/MCC: Inpatient Reimbursement Overview

    138-MOUTH-PROCEDURES-WITHOUT-CC-MCC

    Mouth Procedures without CC/MCC: Inpatient Reimbursement Overview

    139-SALIVARY-GLAND-PROCEDURES

    Salivary Gland Procedures: Inpatient Reimbursement Overview

    140-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-MCC

    Major Head and Neck Procedures with MCC: Inpatient Reimbursement Overview

    141-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-CC

    Major Head and Neck Procedures with CC: Inpatient Reimbursement Overview

    142-MAJOR-HEAD-AND-NECK-PROCEDURES-WITHOUT-CC-MCC

    Major Head and Neck Procedures without CC/MCC: Inpatient Reimbursement Overview

    143-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-MCC

    Other Ear, Nose, Mouth and Throat O.R. Procedures with MCC: Inpatient Reimbursement Overview

    144-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-CC

    Other Ear, Nose, Mouth and Throat O.R. Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.